Oct 14th 2013 - Edison Investment Research today published a report on Biotie Therapies Corp entitled "A Maturing Strategy". In summary, the report says:
The completion of Biotie's portfolio review sets out a new strategic path as the company aims to transition from a search/develop/license model to a more integrated approach, particularly in bringing products to the market. The option to acquire Neurelis for NRL-1 (intranasal diazepam for epilepsy), a product that could be commercialised by Biotie in the US, is a prime example, and we anticipate further deals for assets with similar attributes. Securing a partner for SYN120 and/or co-funding for BTT-1023 in a Phase II study for a rare autoimmune liver disorder are other potential near-term catalysts.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »